Allogene Therapeutics : August 2022 Corporate Presentation

The Next Revolution in Cell Therapy

Leading Today, Defining Tomorrow

August 2022

Legal Disclaimers

To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. ("Allogene," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this Presentation include, but are not limited to, statements regarding: the timing and ability to progress the ALPHA2, UNIVERSAL, IGNITE and TRAVERSE trials, including advancing to the Phase 2 portion of the ALPHA2 trial; the timing and ability to initiate the EXPAND trial for ALLO-647; clinical outcomes, which may materially change as more patient data become available; the ability to manufacture AlloCAR T™ products, including obtaining FDA agreement to use ALLO-501A manufactured at the Company's manufacturing facility for use in the ALPHA2 trial; the projection related to the number of AlloCAR T doses that can be produced at Cell Forge 1 at scale on an annual basis; the potential benefits of AlloCAR T. Various factors may cause differences between Allogene's expectations and actual results as discussed in greater detail in Allogene's filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the quarter ended June 30, 2022.

Caution should be exercised when interpreting results from separate trials involving separate product candidates. There are differences in the clinical trial design, patient populations, follow-up times, and the product candidates themselves, and the results from the clinical trials of autologous products may have no interpretative value on our existing or future results.

Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

2

Allogene: Creating the Allogeneic Cell Therapy Playbook

• Foundational platform technologies
• • AlloCAR TTM
  • TurboCARTM
  • iPSC
  • Allogeneic manufacturing

~350

employees

defining the field and writing the

allogeneic CAR T playbook

>	more patients treated
with AlloCAR TTM
product candidates
than any other
165	allogeneic CAR T
Patients
treated

$686

million

in cash, cash equivalents and investments as of June 30, 2022

1

singular focus on allogeneic cell therapy

3

AlloCAR T: Potential to Break the Bottleneck in Cell Therapy

Limited Manufacturing Slots

Access Only in Specialty CAR T Centers

Disease Progression During Waiting Interval

Manufacturing Failures

Bridging Therapy

Higher Cost

Autologous	Single
CAR T	Manufacturing
Run
Personalized Therapy
	1 Patient Per Run

Single	AlloCAR T
Manufacturing
Run	Pharmaceutical Product

Consistent Product

Immediate Treatment

Scalable Manufacturing

Potential for Outpatient Use

Administration in the Community Setting

Ability to Meet Patient Demand

100+ of Patients Per Run

Restricted Market Expansion/Growth		Untapped Market Potential

4

CONFIDENTIAL

Fully-Integrated Operations Technology Organization

• 170

Full-time Operations

Technology Staff

Process & Analytical

Development

• Proven GMP Processes
• Characterized Unit Operations

Deep

Product

Understanding

Quality & Product

Characterization

• Qualified Release Tests
• Internal unbiased product data analysis

Manufacturing

• 136K ft2 modular facility
• Designed to US and international commercial cGMP standards

~ 20 K

Patients Per Year

Manufacturing Capacity*

Supply Chain

Management

• Qualified Suppliers across all Input Materials
• Ultracold inventory and logistics in place nationally and pending in EU

* Projection for first potential commercial asset, ALLO-501A, at scale

5